|
Immune
System & Diseases
Transfer Factor & Immune Function that affect
Cancer
Natural Killer
Cells in Human Cancer
Human
Carcinongens
Major
Side Effects of Chemotherapy
Chemotherapy Side
Effects Studies comparing the impact of different antiemetics
on HRQL
Immune System Supplement
Increase your natural killer (NK) cells activities with enhanced transfer
factor, natural immune booster for the fight against cancer cells.
Glucose Control Tablet
Pycnogenol (French
maritime pine tree extract) Benefit for Diabetes
Diabetes & Pycnogenol Double
Blinded Study
|
|
|
Leukemia
Transmission |
Human T-cell leukemia virus type I (HTLV-I)
infection and the onset of adult T-cell leukemia (ATL)
Masao Matsuoka,
Institute for Virus
Research, Kyoto University, Kyoto 606-8507, Japan,
Retrovirology 2005, 2:27 doi:10.1186/1742-4690-2-27
© 2005
Matsuoka; licensee BioMed Central Ltd., This is an
Open Access article distributed under the terms of
the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
work is properly cited. |
|
|
|
|
Background
of Human T-cell Leukemia Virus Type I infection and
the onset of Adult T-cell Leukemia
History of humans and Human T-cell Leukemia Virus
Type 1 |
How
does Human T-cell Leukemia Virus type 1
spread in humans?
How
does Human T-cell Leukemia Virus Type 1 replicate and increase its copy number?
|
|
4. How does Human T-cell Leukemia Virus Type 1 (HTLV-I)
transmit and replicate in vivo?
Receptor and
transmission of Human T-cell Leukemia Virus
type 1
Human T-cell
Leukemia Virus Type 1 can infect various
types of cells, such as T-lymphocytes,
B-lymphocytes, monocytes and fibroblasts [46].
Glucose transporter 1 (GLUT-1) has been identified
as a receptor for Human T-cell Leukemia Virus Type 1 and this receptor is
ubiquitously expressed on cell surfaces [47].
However, the Human T-cell Leukemia Virus Type 1 provirus is mainly detected in
CD4-positive lymphocytes, with about 10% in
CD8-positive T-lymphocytes [48].
This situation possibly arises because Tax mainly
induces the increase of CD4-positive T-lymphocytes
in vivo by enhanced proliferation and
suppressed apoptosis.
In Human T-cell Leukemia Virus Type 1-infected
individuals, no virions are detected in the serum.
In addition, the infectivity of free virions is very
poor compared with that of infected cells. These
findings suggest that
Human T-cell
Leukemia Virus Type 1 is spread by
cell-to-cell transmission, rather than by free virions. In vitro analyses of Human T-cell Leukemia Virus
Type 1-infected cells
revealed that HTLV-I-infected cells form "virological
synapses" with uninfected cells. Contact between an
infected cell and a target cell induces the
accumulation of the viral proteins Gag and Env,
viral RNA and microtubules, and the viral complex
subsequently transfers into the target cell [49].
Human T-cell Leukemia Virus type 1 also
spreads in a cell-to-cell manner via such
virological synapses in vivo.
Human T-cell Leukemia Virus Type 1 is mainly
transmitted via three routes: 1) mother-to-infant
transmission (mainly through breast feeding) [50];
2) sexual transmission (mainly from male-to-female);
and 3) parenteral transmission (blood transfusion or
intravenous drug use) [12]. In
either route, HTLV-I-infected cells are essential
for transmission. This was supported by the findings
that fresh frozen plasma from carriers did not cause
transmission [51] and
freeze-thawing of breast milk reduced vertical
transmission [52].
Provirus load and transmission
The provirus load varies
more than 1000-fold among asymptomatic carriers [53].
Since most infected cells are considered to have one
copy of the provirus, the provirus load indicates
the percentage of infected cells among lymphocytes.
The provirus load is relatively constant during the
latent period [53]. Analysis of
naive individuals who seroconvert after marrying an
Human T-cell Leukemia Virus Type
1-seropositive spouse demonstrated that the proviral
gp46 sequences are identical among married couples.
This finding confirmed that HTLV-I is transmitted
from a seropositive individual to an uninfected
spouse. The provirus loads frequently differ between
couples despite infection by the same HTLV-I virus,
indicating that the number of infected cells is
determined by host factors rather than virus itself
[54].
Why does Human T-cell Leukemia Virus Type
1 increase
the number of infected cells by the pleiotropic
actions of Tax? The provirus load in peripheral
blood mononuclear cells (PBMCs) is well correlated
with that in breast milk, and a higher provirus load
in breast milk increases the risk of vertical
transmission of HTLV-I [55,56].
Similarly, a higher provirus load in PBMCs may be
associated with a higher risk of sexual
transmission. Thus, an increase in the number of
infected cells by the actions of accessory genes,
especially tax, facilitates transmission.
Therefore, HTLV-I has strategies that increase the
number of HTLV-I-infected cells via the action of
accessory gene products, thereby increasing the
chance of transmission.
Clonal expansion of Human T-cell Leukemia
Virus Type 1-infected cells
After Human T-cell Leukemia Virus Type
1 infection,
viral proteins such as Tax protein promote the
proliferation of infected cells and also inhibit
apoptosis by their pleiotropic actions. Since the
HTLV-I provirus is randomly integrated into the host
genome, the identification of integration sites
enables to identify each infected clone, and to
trace the kinetics of infected cells in vivo.
Analyses using inverse PCR, which can identify the
integration sites of the HTLV-I provirus, revealed
that the proliferation of infected cells is
oligoclonal, and that infected cells persistently
survive in vivo [57-59].
Importantly, such clonal expansion in carriers is
directly associated with the onset of Adult
T-cell Leukemia [60]. Thus,
the viral strategies to increase the number of HTLV-I-infected
cells work efficiently in most carriers without any
adverse effects. However, the increased number of
infected cells causes an excess
immune reaction,
leading to inflammatory diseases, HAM/TSP, infective
dermatitis [61] or HTLV-I-associated
uveitis [62]. Moreover, such
prolonged proliferation of infected CD4-positive
T-lymphocytes results in the onset of ATL in some
carriers after a long latent period.
Inactivation of Tax expression in Adult T-cell
Leukemia (ATL) cells
As mentioned above, Tax
expression confers advantages and disadvantages on
Human T-cell Leukemia Virus Type
1-infected cells. Although the proliferation of
infected cells is promoted by Tax expression, CTLs
attack the Tax-expressing cells since Tax is their
major target [63]. In HTLV-I-infected
cells, Rex, p30 and HBZ suppress Tax expression. On
the other hand, loss of Tax expression is frequently
observed in leukemic cells. Three mechanisms
have been identified for inactivation of Tax
expression: 1) genetic changes of the tax gene
(nonsense mutations, deletions or insertions) [64,65];
2) DNA methylation of the 5'-LTR [65,66];
and 3) deletion of the 5'-LTR (Figure
2) [67]. Among fresh leukemic
cells isolated from ATL patients, about 60% of
cases do not express the tax gene transcript.
Interestingly, Adult T-cell Leukemia cells
with genetic changes of the tax gene expressed its
transcripts, suggesting that ATL cells do not
silence the transcription when the tax gene is
abortive [65]. Loss of Tax
expression gives ATL cells advantage for their
survival since they can escape from CTLs.
Longer lifespan of Human T-cell Leukemia Virus
type 1-infected cells and cancer
Lymphoid malignancy with
a T-cell origin is rare compared with B-cell
malignancy. Adult T-cell Leukemia shares
hematological, pathological and immunological
features with cutaneous T-cell lymphoma (CTCL;
Sezary syndrome and Mycosis fungoides). The
frequency of CTCL in Japan is estimated to be
one/million/year. On the other hand, the frequency
of ATL among carriers is estimated to be
1000/million/year. From these data, HTLV-I infection
is estimated to increase the risk of T-cell
malignancy by up to 1000-fold in carriers.
Human T-cell Leukemia Virus Type
1 infection confers
a long lifespan on the infected cells due to the pleiotropic actions of Tax, resulting in increased
numbers of infected cells. Such infected cells are
essential for the transmission of HTLV-I. This
strategy to increase the number of infected cells in
vivo is thought to increase the incidence of cancer
in T-cells. What is the mechanism for this
oncogenesis? DNA methylation is known to be
associated with aging. Some genes are
hypermethylated in older people, indicating that DNA
hypermethylation is a physiological phenomenon in
some genes. Under normal circumstances,
T-lymphocytes survive for several years, and
long-lived T-lymphocytes with disordered methylation
should be replaced. However, HTLV-I-infected T-cells
are considered to survive and accumulate abnormal
methylation. The process of oncogenesis is similar
to that of evolution [68]. The
infected cells that are suitable for survival should
be selected in vivo, and epigenetic and genetic
changes of the genome play critical roles in this
selection. Accumulating alterations of the host
genome transform the HTLV-I-infected cells into ATL
cells, and also enable ATL cells to proliferate in
the absence of Tax expression (Figure
2). In the provirus, DNA methylation of the
5'-LTR silences viral transcription in leukemic
cells, which facilitates the escape of ATL cells
from the host immune system [65].
5. Somatic alterations in Adult T-cell Leukemia cells
As described, some
Adult T-cell Leukemia cells can proliferate
without functional Tax protein, suggesting that
somatic (genetic and epigenetic) alterations cause
transcriptional or functional changes to the host
genes. The p53 gene is frequently mutated in various
cancers, and these mutations are associated with
disease progression and a poor prognosis. The
mutation rate of the p53 gene in ATL cells has been
reported to be 36% (4/11) and 30% (3/10) [69-71].
The p16 gene is an inhibitor of cyclin-dependent
kinase 4/6, and blocks the cell cycle. Genetic
changes in this gene (deletion in most cases) have
been described in many types of cancer cells.
Deletion of the p16 gene has also been reported in
ATL cells [72]. Moreover, DNA
methylation of the promoter region of the p16 gene
is also implicated in the suppression of p16 [73].
In addition, genetic changes in the p27KIP1,
RB1/p105 and RB2/p130 genes have been reported in
ATL, although they are relatively rare: 2/42 (4.8%)
for the p27KIP1 gene; 2/40 (5%) for the
RB1/p105 gene; and 1/41 (2.4%) for the RB2/p130
gene) [74]. The fact that higher
frequencies of genetic changes in these tumor
suppressor genes are observed among aggressive forms
of ATL suggests that such genetic changes are
implicated in disease progression.
Fas antigen was the first identified death receptor.
It transduces the death signal by binding of its
ligand, Fas ligand (FasL). Adult T-cell Leukemia
cells highly express Fas antigen on their cell
surface [75], and are highly
susceptible to death signals mediated by agonistic
antibodies to Fas antigen, such as CH-11. Genetic
changes of Fas gene in ATL cells, which confer
resistance to the Fas-mediated signal, have been
reported [76,77].
Normal activated T-lymphocytes express FasL as well
as Fas antigen. Apoptosis induced by autocrine
mechanisms is designated activation-induced cell
death (AICD) and this controls the
immune response [78].
Although ATL cells express Fas antigen, they do not
produce FasL, thereby enabling ATL cells to escape
from AICD. Attempts to isolate hypermethylated genes
from ATL cells identified the EGR3 gene as a
hypermethylated gene compared to PBMCs from carriers
[79]. EGR3 is a transcriptional
factor with a zinc finger domain, that is essential
for transcription of the FasL gene [80].
The finding that EGR3 gene transcription is silenced
in ATL cells could account for the loss of FasL
expression, and the escape of ATL cells from AICD.
Thus, alterations of the Fas (genetic) and EGR3
(epigenetic) genes are examples of ATL cell
evolution in vivo.
Disordered DNA methylation has been identified in
the genome of Adult T-cell Leukemia cells
compared with that of PBMCs from carriers:
hypomethylation is associated with aberrant
expression of the MEL1S gene [81],
while hypermethylation silences transcription of the
p16 [73], EGR3 and KLF4 genes as
well as many others [79]. It is
reasonable to consider that other currently
unidentified genes are involved in such alterations
of the genome in ATL cells, and play roles in
leukemogenesis.
Transcriptome analyses
using DNA microarrays have revealed transcriptional
changes that are specific to Adult T-cell
Leukemia cells. Among 192 up-regulated genes,
the expressions of the tumor suppressor in
lung cancer 1
(TSLC1), caveolin 1 and prostaglandin D2
synthase genes were increased more than 30-fold in
fresh ATL cells compared with normal CD4+ and CD4+,
CD45RO+ T-cells [82]. TSLC1 is a
cell adhesion molecule that acts as a tumor
suppressor in lung
cancer. Although TSLC1 is not expressed on
normal T-lymphocytes, all acute ATL cells show
ectopic TSLC1 expression. Enforced expression of
TSLC1 enhances both the self-aggregation and
adhesion abilities to vascular endothelial cells in
ATL cells. Thus, TSLC1 expression is implicated in
the adhesion or infiltration of ATL cells. By
screening a retrovirus cDNA library from ATL cells,
a gene with oncogenic potency was identified in
NIH3T3 cells, and designated the Tgat gene [83].
|
|
|
Ectopic expression of the Tgat gene is observed in
aggressive forms of Adult T-cell Leukemia, and in vitro experiments
showed that its expression is associated with an
invasive phenotype.
Immune control of Human T-cell Leukemia Virus
Type 1 infection
Pathogenesis of Human T-cell Leukemia Virus Type
1 infection
Treatment of Adult T-cell
Leukemia - the remaining mission and challenges
Two
human retroviruses - Human T-cell Leukemia Virus
Type 1 and HIV-1 |
Resources
|
12. |
|
Blattner WA, Gallo RC: Epidemiology of HTLV-I
and HTLV-II infection.
In Adult T-cell leukemia. Edited by:
Takahashi K. New York, Oxford University Press;
1994:p.45-90. |
| |
|
Return to
citation in text: [1] |
|
|
|
46. |
|
Koyanagi Y, Itoyama Y, Nakamura N, Takamatsu
K, Kira J, Iwamasa T, Goto I, Yamamoto N: In
vivo infection of
human
T-cell leukemia virus type I in
non-T cells.
Virology 1993, 196:25-33. |
| |
|
Return to
citation in text: [1]
|
|
|
|
47. |
|
Manel N, Kim FJ, Kinet S, Taylor N, Sitbon
M, Battini JL: The ubiquitous glucose
transporter GLUT-1 is a receptor for HTLV.
Cell 2003, 115:449-459. |
| |
|
Return to
citation in text: [1]
|
|
|
|
48. |
|
Yasunaga J, Sakai T, Nosaka K, Etoh K,
Tamiya S, Koga S, Mita S, Uchino M, Mitsuya
H, Matsuoka M: Impaired production of naive
T lymphocytes in
human T-cell leukemia
virus type I-infected individuals: its
implications in the immunodeficient state.
Blood 2001, 97:3177-3183. |
| |
|
Return to
citation in text: [1] |
|
|
|
49. |
|
Igakura T, Stinchcombe JC, Goon PK, Taylor
GP, Weber JN, Griffiths GM, Tanaka Y, Osame
M, Bangham CR: Spread of HTLV-I between
lymphocytes by virus-induced polarization of
the cytoskeleton.
Science 2003, 299:1713-1716. |
| |
|
Return to
citation in text: [1]
|
|
|
|
50. |
|
Hino S: Primary prevention of ATL.
In Two decades of
adult
T-cell leukemia and HTLV-I
research. Edited by: Sugamura K, Uchiyama T,
Matsuoka M and Kannagi M. Tokyo, Japan
Sicentific Societies Press; 2003:241-251. |
| |
|
Return to
citation in text: [1]
|
|
|
|
51. |
|
Okochi K, Sato H, Hinuma Y: A retrospective
study on transmission of
adult T cell
leukemia virus by blood transfusion:
seroconversion in recipients.
Vox Sang 1984, 46:245-253. |
| |
|
Return to
citation in text: [1]
|
|
|
|
52. |
|
Ando Y, Ekuni Y, Matsumoto Y, Nakano S,
Saito K, Kakimoto K, Tanigawa T, Kawa M,
Toyama T: Long-term serological outcome of
infants who received frozen-thawed milk from
human T-lymphotropic virus type-I positive
mothers.
J Obstet Gynaecol Res 2004, 30:436-438.
|
| |
|
Return to
citation in text: [1]
|
|
|
|
53. |
|
Etoh K, Yamaguchi K, Tokudome S, Watanabe T,
Okayama A, Stuver S, Mueller N, Takatsuki K,
Matsuoka M: Rapid quantification of HTLV-I
provirus load: detection of monoclonal
proliferation of HTLV-I-infected cells among
blood donors.
Int J Cancer 1999, 81:859-864. |
| |
|
Return to
citation in text: [1]
[2] |
|
|
|
54. |
|
Iga M, Okayama A, Stuver S, Matsuoka M,
Mueller N, Aoki M, Mitsuya H, Tachibana N,
Tsubouchi H: Genetic evidence of
transmission of human T cell lymphotropic
virus type 1 between spouses.
J Infect Dis 2002, 185:691-695. |
| |
|
Return to
citation in text: [1]
|
|
|
|
55. |
|
Li HC, Biggar RJ, Miley WJ, Maloney EM,
Cranston B, Hanchard B, Hisada M: Provirus
load in breast milk and risk of
mother-to-child transmission of human T
lymphotropic virus type I.
J Infect Dis 2004, 190:1275-1278.
|
| |
|
Return to
citation in text: [1]
|
|
|
|
56. |
|
Hisada M, Maloney EM, Sawada T, Miley WJ,
Palmer P, Hanchard B, Goedert JJ, Manns A:
Virus markers associated with vertical
transmission of human T lymphotropic virus
type 1 in Jamaica.
Clin Infect Dis 2002, 34:1551-1557.
|
| |
|
Return to
citation in text: [1]
|
|
|
|
57. |
|
Etoh K, Tamiya S, Yamaguchi K, Okayama A,
Tsubouchi H, Ideta T, Mueller N, Takatsuki
K, Matsuoka M: Persistent clonal
proliferation of human T-lymphotropic virus
type I-infected cells in vivo.
Cancer Res 1997, 57:4862-4867. |
| |
|
Return to
citation in text: [1]
|
|
|
|
58.
|
|
Cavrois M, Leclercq I, Gout O, Gessain A,
Wain-Hobson S, Wattel E: Persistent
oligoclonal expansion of
human
T-cell leukemia virus type 1-infected
circulating cells in patients with Tropical
spastic paraparesis/HTLV-1 associated
myelopathy.
Oncogene 1998, 17:77-82. |
| |
|
Return to
citation in text: [1]
|
|
|
|
59.
|
|
Matsuoka M: Human T-cell leukemia virus
type I and
adult
T-cell leukemia.
Oncogene 2003, 22:5131-5140. |
| |
|
Return to
citation in text: [1]
|
|
|
|
60. |
|
Okayama A, Stuver S, Matsuoka M, Ishizaki J,
Tanaka G, Kubuki Y, Mueller N, Hsieh CC,
Tachibana N, Tsubouchi H: Role of HTLV-1
proviral DNA load and clonality in the
development of
adult T-cell leukemia/lymphoma
in asymptomatic carriers.
Int J Cancer 2004, 110:621-625. |
| |
|
Return to
citation in text: [1]
|
|
|
|
61. |
|
LaGrenade L, Hanchard B, Fletcher V,
Cranston B, Blattner W: Infective dermatitis
of Jamaican children: a marker for HTLV-I
infection.
Lancet 1990, 336:1345-1347. |
| |
|
Return to
citation in text: [1]
|
|
|
|
62. |
|
Nakao K, Ohba N, Matsumoto M: Noninfectious
anterior uveitis in patients infected with
human T-lymphotropic virus type I.
Jpn J Ophthalmol 1989, 33:472-481.
|
| |
|
Return to
citation in text: [1]
|
|
|
|
63. |
|
Kannagi M, Harada S, Maruyama I, Inoko H,
Igarashi H, Kuwashima G, Sato S, Morita M,
Kidokoro M, Sugimoto M, et al.:
Predominant recognition of
human T cell
leukemia virus type I (HTLV-I) pX gene
products by human CD8+ cytotoxic T cells
directed against HTLV- I-infected cells.
Int Immunol 1991, 3:761-767. |
| |
|
Return to
citation in text: [1] |
|
|
|
64. |
|
Furukawa Y, Kubota R, Tara M, Izumo S, Osame
M: Existence of escape mutant in HTLV-I tax
during the development of
adult
T-cell leukemia.
Blood 2001, 97:987-993. |
| |
|
Return to
citation in text: [1]
|
|
|
|
65. |
|
Takeda S, Maeda M, Morikawa S, Taniguchi Y,
Yasunaga J, Nosaka K, Tanaka Y, Matsuoka M:
Genetic and epigenetic inactivation of tax
gene in
adult T-cell leukemia cells.
Int J Cancer 2004, 109:559-567. |
| |
|
Return to
citation in text: [1]
[2]
[3]
[4]
|
|
|
|
66. |
|
Koiwa T, Hamano-Usami A, Ishida T, Okayama
A, Yamaguchi K, Kamihira S, Watanabe T:
5'-long terminal repeat-selective CpG
methylation of latent
human
T-cell leukemia virus type 1 provirus in vitro and in vivo.
J Virol 2002, 76:9389-9397. |
| |
|
Return to
citation in text: [1]
|
|
|
|
67. |
|
Tamiya S, Matsuoka M, Etoh K, Watanabe T,
Kamihira S, Yamaguchi K, Takatsuki K: Two
types of defective human T-lymphotropic
virus type I provirus in
adult
T-cell leukemia.
Blood 1996, 88:3065-3073. |
| |
|
Return to
citation in text: [1]
|
|
|
|
68. |
|
Tomlinson I, Bodmer W: Selection, the
mutation rate and cancer: ensuring that the
tail does not wag the dog.
Nat Med 1999, 5:11-12. |
| |
|
Return to
citation in text: [1]
|
|
|
|
69. |
|
Sakashita A, Hattori T, Miller CW, Suzushima
H, Asou N, Takatsuki K, Koeffler HP:
Mutations of the p53 gene in
adult
T-cell leukemia.
Blood 1992, 79:477-480. |
| |
|
Return to
citation in text: [1]
|
|
|
|
70.
|
|
Cesarman E, Chadburn A, Inghirami G, Gaidano
G, Knowles DM: Structural and functional
analysis of oncogenes and tumor suppressor
genes in adult T-cell leukemia/lymphoma
shows frequent p53 mutations.
Blood 1992, 80:3205-3216. |
| |
|
Return to
citation in text: [1]
|
|
|
|
71.
|
|
Nishimura S, Asou N, Suzushima H, Okubo T,
Fujimoto T, Osato M, Yamasaki H, Lisha L,
Takatsuki K: p53 gene mutation and loss of
heterozygosity are associated with increased
risk of disease progression in
adult T
cell leukemia.
Leukemia 1995, 9:598-604.
|
| |
|
Return to
citation in text: [1]
|
|
|
|
72. |
|
Hatta Y, Hirama T, Miller CW, Yamada Y,
Tomonaga M, Koeffler HP: Homozygous
deletions of the p15 (MTS2) and p16
(CDKN2/MTS1) genes in
adult
T-cell leukemia.
Blood 1995, 85:2699-2704. |
| |
|
Return to
citation in text: [1]
|
|
|
|
73. |
|
Nosaka K, Maeda M, Tamiya S, Sakai T,
Mitsuya H, Matsuoka M: Increasing
methylation of the CDKN2A gene is associated
with the progression of
adult
T-cell leukemia.
Cancer Res 2000, 60:1043-1048. |
| |
|
Return to
citation in text: [1]
[2]
|
|
|
|
74. |
|
Morosetti R, Kawamata N, Gombart AF, Miller
CW, Hatta Y, Hirama T, Said JW, Tomonaga M,
Koeffler HP: Alterations of the p27KIP1 gene
in
non-Hodgkin's lymphomas and
adult
T-cell leukemia/lymphoma.
Blood 1995, 86:1924-1930. |
| |
|
Return to
citation in text: [1]
|
|
|
|
75. |
|
Nagata S: Fas ligand-induced apoptosis.
Annu Rev Genet 1999, 33:29-55. |
| |
|
Return to
citation in text: [1]
|
|
|
|
76. |
|
Tamiya S, Etoh K, Suzushima H, Takatsuki K,
Matsuoka M: Mutation of CD95 (Fas/Apo-1)
gene in
adult T-cell leukemia cells.
Blood 1998, 91:3935-3942. |
| |
|
Return to
citation in text: [1]
|
|
|
|
77. |
|
Maeda T, Yamada Y, Moriuchi R, Sugahara K,
Tsuruda K, Joh T, Atogami S, Tsukasaki K,
Tomonaga M, Kamihira S: Fas gene mutation in
the progression of
adult T
cell leukemia.
J Exp Med 1999, 189:1063-1071. |
| |
|
Return to
citation in text: [1]
|
|
|
|
78. |
|
Krueger A, Fas SC, Baumann S, Krammer PH:
The role of CD95 in th | | | | |